—

Print
Save
Email this link

Share Link

Copy this link, or click below to email it to a friend
Email this link
or copy the link directly:

https://erc.bioscientifica.com/search?access=all&pageSize=10&q=%22neuroendocrine+carcinoma%22&sort=relevance&t=ERC-insulinglucagon100
The link was not copied. Your current browser may not support copying via this button.

Link copied successfully

Search Results

You are looking at 1 - 1 of 1 items for :

"neuroendocrine carcinoma" x

100 years of Insulin and Glucagon x

Refine by access: All content x

Clear All

Emerging therapies for advanced insulinomas and glucagonomas

Krystallenia I Alexandraki

Krystallenia I Alexandraki Department of Surgery, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Krystallenia I Alexandraki in
Google Scholar
PubMed

Gregory A Kaltsas

Gregory A Kaltsas Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Gregory A Kaltsas in
Google Scholar
PubMed

, and

Simona Grozinsky-Glasberg

Simona Grozinsky-Glasberg Department of Endocrinology and Metabolism, Neuroendocrine Tumor Unit, ENETS Center of Excellence, Hadassah Medical Organization and Faculty of Medicine, the Hebrew University, Jerusalem, Israel

Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed

-differentiated neuroendocrine carcinoma (NEC), either functioning or nonfunctioning and the combination cisplatin/etoposide is the most popular ( Baudin et al. 2013 ). Overall, 5-fluorouracil (5-FU), doxorubicin, and streptozotocin have been commonly used in the treatment of